Dear Editor,

We have read with great interest the excellent review by Kim *et al*.[@ref1] which reports the tools available in interventional radiology (IR) to face the frustrating problem of impotence. The social and psychological implication of this pathology drove the effort of scientific medicine searching for a solution for centuries.[@ref2]

As known, the etiology of vasculogenic Erectile Dysfunction (ED) is complex and multifactorial providing either arterial or venous dysfunction, and the precise interplay of all physiologic mechanisms involved is not completely understood. Vasculogenic ED offers the opportunity to exploit modern IR techniques restoring compromised arterial inflow in case of artery insufficiency or reducing venous outflow in case of veno-occlusive dysfunction (VOD).

The paper exhaustively reports the state-of-the art on this topic discussing endovascular embolization techniques and the inherent limitations. The ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Suboptimal Response to PDE5 Inhibitors) trial well represents a modern option to treat the inadequate arterial inflow to corpora cavernosa.[@ref3] However, normal pelvic vascular anatomy and the correlation between the pelvic arterial disease and the ED are still not clear, and further studies are necessary to better define the role of pudendal stenting.[@ref1]

The physiology of VOD was demonstrated in the 1970s;[@ref4] patients suffering of ED due to VOD, usually have damage to the corporeal smooth musculature or the tunica albuginea, or both, which results in impairments of vascular dilation. Hence, penis veins were the subject of medical and nonmedical therapies for centuries as the "penile ring" system could prove.[@ref5]

Concerning the VOD and the penis deep dorsal vein (DDV), the option of surgical ligation, although developed some decades ago, was improved in the last years with encouraging outcomes.[@ref6] Kim *et al*.[@ref1] clearly underline the role of the embolization techniques and their limitations dealing with VOD. The authors report the work of Aschenbach *et al*.[@ref7] which obtained an 88.8% clinical success rate after endovascular internal pudendal vein embolization therapy with histoacryl-lipiodol using a trans-femoral approach. The retrograde approach of the technique requires a bilateral selective catheterization of the internal pudendal veins without the possibility of embolizing the external pudendal vein, the periprostatic venous plexus, and the DDV. In fact, many papers were published referring to the embolization techniques of the deep dorsal vein and the related efferents (internal and external pudendal veins and the periprostatic venous plexus).[@ref8][@ref9]

At our institution, we developed a minimally invasive technique with an anterograde approach of the DDV under US-guided puncture.[@ref10] Subsequently, we performed the selective catheterization and embolization under fluoroscopic guidance of the periprostatic plexus and both the internal and external pudendal veins, using N-butyl-2-cyanoacrylate (NBCA). We are convinced that this approach allows an optimal occlusion of the venous outflow from the corpora cavernosa. The anterograde approach improves catheter placement and maneuverability owing to the short distance between the vascular access and the point of glue delivery; moreover, the downstream glue delivery allows a controlled and safe embolization.

Concerning this issue, we would like to report the case of a 30-year-old man, suffering of VOD, who underwent a trans-femoral internal pudendal vein embolization. After 6 months of clinical success, the patient had a recurrence. Ten months later, the patient referred at our institution, complaining for an ED not responding to oral pharmacotherapy (PDE5 inhibitors). The patient first underwent a clinical evaluation by an endocrinologist to rule out psychogenic causes; then, a color Doppler flow analysis confirmed a significant and persistent VOD (high systolic flow rate \>25 cm s^−1^ and a persistent end-diastolic velocity, EDV, \>5 cm s^−1^, 15 min after the intracavernosal injection of 20 mg alprostadil, with a resistive index of 0.75) and we decided to perform the embolization of the periprostatic venous plexus with the aforementioned anterograde approach. The venography showed a persistent bilateral venous leakage despite the previous retrograde embolization with coils (**Figure [1a](#F1){ref-type="fig"}** and **[1b](#F1){ref-type="fig"}**). The anterograde periprostatic plexus embolization was successfully performed (**Figure [1c](#F1){ref-type="fig"}** and **[1d](#F1){ref-type="fig"}**) and confirmed at color Doppler flow analysis 2 months after the procedure (EDV \<5 cm s^−1^). The patient is still experiencing clinical benefits without diminishing the improvement of the erectile function at a 15-month follow-up.

![**(a)** After the vein was punctured with a 20-gauge needle, a 0.018" guide wire was gently advanced under fluoroscopic guidance; note the coil delivered in the previous treatment (black arrow). **(b)** Venography showing the persistent bilateral venous leakage despite the previous retrograde embolization with coils (black arrows). **(c)** Contrast venography after partial embolization (N-butyl-2-cyanoacrylate and Lipiodol in a 1:1 ratio) of the internal pudendal veins showing the maintained partial patency of the left internal and external pudendal veins. **(d)** Final venography showing the complete embolization of the periprostatic venous plexus (note the radiopaque embolic mixture without subtraction).](AJA-19-509-g001){#F1}

In our institution, we are recruiting more patients to update the results of anterograde embolization. There are small evidence concerning these promising endovascular techniques and we need further studies to better understand the long-term follow-up. Even so, embolization techniques should be considered in all the cases of confirmed ED due to VOD, especially in young patients. Although the technique is not always successful restoring completely the erectile function, in most cases, the patients have a satisfactory erectile function just resorting to oral pharmacotherapy (PDE5 inhibitors), delaying the time to penile prosthesis.
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